SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Mutation C134W

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There are 3 clinical trials

Clinical Trials


1 Open Phase II Study of Ketoconazole as Inhibitor of the Enzyme CYP17 in Locally Advanced or Disseminated Granulosa Cell Tumour of Ovary. GreKo Study.

Our proposal is to conduct an open phase II clinical trial that allows us to explore the activity of ketoconazole, an inhibitor of the enzyme CYP17, in ovarian granulosa tumors similar to what has been done in prostate cancer. The rational is based on dysregulation that FOXL2 mutations present in almost all granulosa tumors result in the expression of CYP17 that appears to be key in the development and progression of the disease. This work would represent the first attempt to address the treatment of ovarian granulosa cancer with a molecular solid rational, drawing on the recent identification of the mutation "leader" of this tumor. If succeed provide a widely available therapeutic alternative compared with current cancer therapies, with low toxicity. In addition it would open a new line of research with CYP17 enzyme inhibitors that could alter the course and outcome, usually fatal, in advanced stages of disease.

NCT01584297 Granulosa Cell Tumour of the Ovary Drug: Ketoconazole
MeSH: Granulosa Cell Tumor

- Availability of sufficient biopsy material to confirm the diagnosis by a centralized pathologist and determination of the FOXL2 402C mutation ā†’ G (C134W). - Metastatic or unresectable disease. --- C134W ---

Primary Outcomes

Description: The primary endpoint is overall response rate, defined as the proportion of patients with response defined as complete or partial response according to RECIST CRITERIA 1.1 measured by an external evaluator

Measure: Overall response rate

Time: Every 8 weeks

Secondary Outcomes

Description: Clinical benefit defined as stable disease for more than 6 months plus complete and partial response rates, measured by an external evaluator.

Measure: Clinical benefit

Time: Every 8 weeks

Description: Progression-free survival is defined as the time since the start of treatment until progressive disease assessed (through evaluation by an external radiologist) according to RECIST 1.1, or death by any cause.

Measure: Progression-free survival

Time: Every 8 weeks

Description: Overall survival, defined as the time since the start of treatment until the patient dies by any cause.

Measure: Overall survival

Time: Untill death

Description: Quality of life measured by the validated in Spanish EORTC QLQ-C30 questionnaire.

Measure: Quality of life

Time: Every 4 weeks

Description: Toxicities will be classified according to the NCI-CTCAE v4.03

Measure: Safety profile

Time: Every 4 weeks

2 Open Label Phase II Clinical Trial of Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors. The Greko II Study.

Granulosa Cell ovarian carcinoma is an infrequent subtype of neoplasia well differentiated from epithelial tumors. They account for 5% of all ovarian malignancies and, with an incidence of 0.4-1.2 cases per 100000 habitants, is considered as a rare disease. Though most cases are identified at initial stages and can be cured through surgical resection, distant recurrences have been documented even 10 years after resecting the primary tumor. At advanced stage it is a lethal disease. Unfortunately because of the low incidence of this disease randomized clinical trials are lacking. In fact current evidence for treatment is provided by case reports, retrospective studies and phase II clinical trials performed one decade ago. Orteronel, a novel, orally active, selective inhibitor of 17,20-lyase, is being developed as an endocrine therapy for relevant hormone-sensitive cancers such as prostate cancer and breast cancer. Orteronel is expected to suppress sex hormone levels in both circulation and relevant hormone-dependent malignant tissue. Since sex hormone overproduction has been demonstrated in granulosa cell ovarian tumors and seems to play a major role in this disease, this study will assess the efficacy or orteronel treating such tumors.

NCT02101684 Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors Drug: Orteronel 300mg BID
MeSH: Ovarian Neoplasms
HPO: Ovarian neoplasm

- Availability of sufficient biopsy material to confirm the malignant diagnosis of granulosa cell ovarian tumor by a centralized pathologist and to perform the determine the FOXL2 402C mutation ā†’ G (C134W). --- C134W ---

Primary Outcomes

Description: Clinical benefit is defined as the average of patients with radiological response (partial or complete) plus stable disease longer than 6 months by RECIST 1.1 criteria

Measure: Clinical benefit at 6 months

Time: 6 months

Secondary Outcomes

Description: Overall Response Rate according to RECIST 1.1 criteria.

Measure: Overall Response Rate

Time: Every 8 weeks, during 6 months

Description: Progression Free Survival defined as the time from the administration of the first dose of treatment to disease progression or death from any cause.

Measure: Progression free survival

Time: Every 8 weeks, during 6 months

Description: Overall Survival defined as the time from first dose of treatment to patient death from any cause

Measure: Overall Survival

Time: Every 12 weeks, untill death

Description: Significant reduction of sex hormones production will be considered as at least a reduction to half the basal level confirmed in one determination one month apart.

Measure: Reduction of sex hormones production.

Time: Every 8 weeks, during 6 months

Description: Frequency of each adverse event per patient

Measure: Toxicity profile

Time: Every 4 weeks, untill end of treatment (6 months estimated)

3 Open Label Phase II Clinical Trial of Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GreKo III Study

The good tolerability profile of enzalutamide, the fact that the administration of steroids is not necessary and the impressive results achieved in prostate cancer, make this drug an ideal candidate to be tested in ovarian granulosa cancer, a tumor that could somehow be considered as "female prostate cancer".

NCT03464201 Ovarian Cancer Drug: Enzalutamide 40 MG
MeSH: Ovarian Neoplasms
HPO: Ovarian neoplasm

Inclusion Criteria: - Patients who have given written informed consent - Women aged 18 years or over - Eastern Cooperative Oncology Group (ECOG) ā‰¤ 1 - Diagnosis of histologically confirmed ovarian granulose carcinoma - Availability of sufficient biopsy material for confirmation of the diagnosis by a centralized pathologist and determination of the mutation FOXL2402Cā†’ G(C134W). --- C134W ---

Primary Outcomes

Description: Number of responses according to RECIST 1.1 criteria

Measure: Overall response rate (ORR)

Time: Up to 6 months

Secondary Outcomes

Description: Stabilization of disease plus the sum of partial and complete responses according to RECIST 1.1 criteria.

Measure: Clinical benefit rate

Time: Up to 6 months

Description: Number of progression of the disease according to RECIST 1.1 criteria or death of the patient for any cause

Measure: Progression-free survival (PFS)

Time: Up to 6 months

Description: Number of deaths for any cause.

Measure: Overall survival (OS)

Time: Up to 6 months

Description: Number of Adverse Events per patient

Measure: Incidence of Treatment-Emergent Adverse Events

Time: Up to 6 months


HPO Nodes


Ovarian neoplasm
Genes 86
VAMP7 ZFPM2 CTNNB1 PTEN AKT1 WT1 FGFR2 AKT1 OPCML SOX9 BRCA2 BRCA1 PTEN MLH1 SUFU EWSR1 PMS2 IDH1 LMNA RAD51C RAD51C STAG3 GATA4 PALLD PIK3CA CHEK2 BRIP1 MRE11 FGFR2 TP53 RAD51D PRKN MSH6 EPCAM WT1 NR0B1 WT1 KRAS DICER1 TGFBR2 IDH2 SRY BRCA1 FAN1 DMRT3 MSH3 TP53 KRAS NR5A1 INHBA RNF43 KEAP1 DICER1 BARD1 SMAD4 RAD50 MSH2 NBN WNT10A C11ORF95 MLH3 PTCH2 CDH1 WRN PTEN PALB2 MAP3K1 PIK3CA RELA MAP3K1 PALB2 WT1 PMS2 BRCA2 PTEN BRCA1 RAD51 BRCA1 BRCA2 PTCH1 FLI1 PTEN PMS1 PTCH1 CDKN2A WWOX